US Approves Breakthrough Pancreatic Cancer Treatment for ‘Undruggable’ Proteins

FDA Approval Details for Daraxonrasib

The FDA granted expedited approval for daraxonrasib, which will be sold under the brand name Rasonque by California-based Revolution Medicines, according to company announcements. A one-month supply costs approximately US$39,800. Regulators approved the treatment more than six months ahead of their target date. “It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible,” acting FDA commissioner Kyle Diamantas said in a statement reported by The Associated Press.

Clinical Trial Survival Rates and Comparison

In a company-funded study of 500 patients whose spreading cancer had stopped responding to prior treatments, participants taking a daily dose of daraxonrasib lived for a median of 13.2 months, compared with 6.7 months for patients receiving standard chemotherapy regimens, according to data cited by The Associated Press. While previous standard care involved toxic and largely ineffective chemotherapy that often left patients bedridden, according to University of North Carolina researcher Channing Der, the new oral treatment provides a significant quality of life difference with fewer severe side effects.

Targeting the Undruggable Ras Protein

Mutated K-Ras proteins drive uncontrolled cell proliferation in 90 percent of pancreatic cancers, roughly 40 percent of colorectal cancers, and up to 30 percent of lung cancers, according to Channing Der. While K-Ras was discovered in 1982, it long resisted targeted therapies because it lacked promising crevices for small molecules to bind. Revolution Medicines bypassed this obstacle by engineering daraxonrasib to act as a molecular glue, binding to a ubiquitous protein called cyclophilin A to form a binary complex that shuts down all three human Ras proteins, regardless of the specific mutation.

Side Effects and Drug Resistance

By interfering with Ras proteins in normal tissues, daraxonrasib produces side effects including rashes and gastrointestinal symptoms. “Normal cells are also targeted, but normal cells don’t have the same dependency on Ras signalling as cancer cells, so you get a nice therapeutic window,” said Dana-Farber Cancer Institute cancer immunologist Stephanie Dougan. Dougan also noted that tumors eventually display signs of developing resistance to Ras inhibition, meaning the treatment functions as an option rather than a complete cure.

Future Outlook and Other Cancers

Researchers are evaluating whether the drug’s efficacy will move it into first-line therapy rather than strictly for patients who have failed prior treatments. According to analysis by Channing Der and his colleagues, 79 anti-Ras drugs are currently active across more than 200 clinical trials, with 16 in phase 3 trials. Scientists hope the approach will open doors for treating lung and colorectal cancers, and potentially help boost the effectiveness of immunotherapies by keeping tumors stable or regressing for months to give T-cells an opening.

Frequently Asked Questions

• What is daraxonrasib?

  Daraxonrasib is an FDA-approved daily pill developed by Revolution Medicines that targets and blocks mutated Ras proteins involved in tumor growth.

• How much does Rasonque cost?

  According to Revolution Medicines, a one-month supply of the drug sold under the brand name Rasonque costs approximately US$39,800.

• What are the survival rates for patients taking the new drug?

  Clinical trial participants taking daraxonrasib achieved a median survival time of 13.2 months, compared to 6.7 months for patients receiving standard chemotherapy.

• What types of cancer involve Ras mutations?

  Mutated K-Ras is present in approximately 90 percent of pancreatic cancers, 40 percent of colorectal cancers, and up to 30 percent of lung cancers, according to researchers.